These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Norplant's high cost may prohibit use in Title 10 clinics.
    Journal: Contracept Technol Update; 1991 Apr; 12(4):49-52. PubMed ID: 12316798.
    Abstract:
    The article discusses the prohibitive cost of Norplant for the Title 10 low-income population served in public family planning clinics in the U.S. It is argued that it's unfair for U.S. users to pay $350 to Wyeth- Ayerst when another pharmaceutical company provides developing countries with Norplant at a cost of $14 - 23. Although the public sector and private foundations funded the development, it was explained that the company needs to recoup the investment in training and education. Medicaid and third party payers such as insurance companies will reimburse for the higher price, but if the public sector price is lowered, then the company would not make a profit and everyone would have argued for the reimbursement at the lower cost. It was suggested that a boycott of American Home Products, Wyeth-Ayerst's parent company, be made. Public family planning providers who are particularly low in funding reflect that their budget of $30,000 would only provide 85 users, and identified in this circumstance by drug abusers and multiple pregnancy women, and the need for teenagers remains unfulfilled. Another remarked that the client population served is 4700 with $54,000 in funding, which is already accounted for. The general trend of comments was that for low income women the cost is to high.
    [Abstract] [Full Text] [Related] [New Search]